Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations

(2015) Katsuhiko Nosho et al.   NEOPLASIA

Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

(2014) Joseph D. Valentino et al.   CLINICAL CANCER RESEARCH

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

(2014) Carolyn D. Britten et al.   INVESTIGATIONAL NEW DRUGS

Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series

(2013) Hengmiao Cheng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors

(2013) Karen E. Sheppard et al.   EUROPEAN JOURNAL OF CANCER

BRAF inhibitors in cancer therapy

(2013) Carolina Hertzman Johansson et al.   PHARMACOLOGY & THERAPEUTICS

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma

(2013) R. B. Corcoran et al.   Science Translational Medicine

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models

(2013) Todd M. Pitts et al.   Frontiers in Pharmacology

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

(2012) G. Migliardi et al.   CLINICAL CANCER RESEARCH

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

(2012) M. Mao et al.   CLINICAL CANCER RESEARCH

Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials

(2012) R. Dienstmann et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer

(2012) Ming Yu et al.   Therapeutic Advances in Gastroenterology

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

(2011) Peter D. Boasberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Current and future directions in mammalian target of rapamycin inhibitors development

(2011) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

(2011) J. Yuan et al.   MOLECULAR CANCER THERAPEUTICS

Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

(2010) Kathrin Zitzmann et al.   CANCER LETTERS

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

(2010) T. M. Pitts et al.   CLINICAL CANCER RESEARCH

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

(2010) E. B. Haura et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

(2010) Jaafar Bennouna et al.   INVESTIGATIONAL NEW DRUGS

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo

(2010) Y. C. Henderson et al.   MOLECULAR CANCER THERAPEUTICS

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE